Anthem Biosciences IPO - Listing Performance & Details

Anthem Biosciences Limited was incorporated in 2006 and is headquartered in Bengaluru, Karnataka. It works in the pharmaceutical services sector as a contract research, development and manufacturing organisation (CRDMO).

The company offers integrated services across the drug development lifecycle, from discovery and development to manufacturing, covering both small molecules and biologics, alongside a specialty ingredients business that manufactures fermentation-based products including probiotics, enzymes, peptides, nutritional actives and vitamin analogues. It operates two facilities in Karnataka with a combined capacity of 270 kL for custom synthesis and 142 kL for fermentation, with a third facility under construction at Harohalli. As of September 2024, it served more than 550 customers across over 44 countries and was working across 196 active projects. The promoters are Ajay Bhardwaj (Chairman, Managing Director and CEO), Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.

Revenue from operations rose 34.3% to Rs 1,419 crore in FY24 from Rs 1,056 crore in FY23, though profit after tax declined to Rs 365 crore in FY24 from Rs 385 crore in FY23, as per the DRHP. The IPO was a mainboard book-built issue of about Rs 3,395 crore on the NSE and BSE, structured entirely as an offer for sale by existing shareholders including the promoters, priced at Rs 540-570 per share, and it listed on 17 July 2025. As the offer was entirely an offer for sale, the company did not receive any proceeds from the issue, with the entire amount going to the selling shareholders.